Showing results (991-1000 of 1,104) with videos related to

Sort By:
Pageof 111
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Oncogene|January 26, 2016
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell propertiesA N Paranjape, R Soundararajan, S J Werden, et al.
Oncogene|September 2, 2021
P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasisMing Zhu, Ruiqing Peng, Xin Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasesPaul Mathew, Peter F Thall, Corazon D Bucana, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
JCO Oncology Practice|November 7, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone TherapyNeha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone AcetateGerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Oncotarget|November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testisMehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
Science Translational Medicine|April 3, 2020
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerSumit K Subudhi, Luis Vence, Hao Zhao, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Pageof 111